Japan

Overview

In 2024, ABE & PARTNERS experienced a bountiful year with four successful decisions and zero losses. Notably, they achieved victories representing various pharmaceutical giants. ABE & PARTNERS notably secured a triumph for a Japanese pharmaceutical company by invalidating all claims of an Indian pharmaceutical company’s patent linked to the Zika virus vaccine. Additionally, they represented a US pharmaceutical company, overturning the JPO’s cancellation notice and maintaining the patent’s claims unaltered. Furthermore, in a significant legal battle representing Bayer Healthcare and Regeneron Pharmaceuticals against Samsung Bioepis, ABE & PARTNERS effectively quashed Samsung Bioepis’ unfair competition claim. The Regeneron case was concluded with a dismissal decision by the IP High Court in 2025. These cases form part of a broader global litigation landscape between Regeneron/Bayer and biosimilar companies concerning Eylea, a prominent biopharmaceutical medicinal drug.